Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sprycel

- PMLiVE

EC approves BMS cell therapy for multiple myeloma

The approval of Abecma is based on “rapid, deep and durable” trial responses

- PMLiVE

NICE approval for Lilly’s Verzenios is “fantastic news for thousands of women”

NICE declares Lilly’s breast cancer drug to be cost-effective, allowing routine use on the NHS

- PMLiVE

BMS’ Q2 results beat expectations with strong performance across core therapy areas

In Q2, BMS’ revenue came in at $11.7bn, a 16% increase on the same period last year

- PMLiVE

NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments

The proposed Innovative Medicines Fund is an extension of the existing Cancer Drugs Fund

- PMLiVE

The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals how life...

Avalere Health

- PMLiVE

UK’s CMA fines drugmakers £260m for overcharging NHS for steroid med

Three of the ten companies named in CMA’s statement said they disagreed with the decision and would be appealing against the fines

- PMLiVE

UK Supreme Court rules in favour of Servier in NHS patent lawsuit

The NHS alleged that the French pharma company tried to block sales of generics versions of its drug Coversyl

We must be candid about our use of healthcare data if we want to win back public trust

As the government announces a delay to a new GP data sharing initiative amid privacy concerns, Gareth Thomas, Managing Director of Wilmington Healthcare, explains why industry must move fast to...

Wilmington Healthcare

- PMLiVE

BMS’s oral AML therapy Onureg receives EU approval

Onureg is the oral version of Vidaza, two of the drugs BMS gained as part of its acquisition of Celgene in 2019

- PMLiVE

BMS and Eisai to collaborate in deal worth up to $3.1bn

The two companies will work on developing a drug for endometrial, ovarian, lung and breast cancers

- PMLiVE

BMS’ Zeposia gains FDA approval in ulcerative colitis

Treatment was initially approved in 2020 for multiple sclerosis

- PMLiVE

Wilmington Healthcare appoints new Solutions Director

Kirsty Fryer has been promoted to the role of Solutions Director for Wilmington Healthcare

Wilmington Healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links